Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

Anna‐Janina Behrens(University of Oxford), Snežana Vasiljević(University of Oxford), Laura K. Pritchard(University of Oxford), David J. Harvey(University of Oxford), Rajinder S Andev(Guy's Hospital), Stefanie A. Krumm(Guy's Hospital), Weston B. Struwe(University of Oxford), Albert Cupo(Cornell University), Abhinav Kumar(University of Oxford), Nicole Zitzmann(University of Oxford), Gemma E. Seabright(University of Oxford), Holger Kramer(University of Oxford), Daniel I. R. Spencer(Culham Science Centre), Louise Royle(Culham Science Centre), Jeong Hyun Lee(Scripps Research Institute), Per Johan Klasse(Cornell University), Dennis R. Burton(Scripps Research Institute), Ian A. Wilson(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Rogier W. Sanders(Cornell University), John P. Moore(Cornell University), Katie J. Doores(Guy's Hospital), Max Crispin(University of Oxford)
Cell Reports
March 1, 2016
Cited by 278Open Access
Full Text

Abstract

The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it from immune surveillance. The high density of glycans on the trimer surface imposes steric constraints limiting the actions of glycan-processing enzymes, so that multiple under-processed structures remain on specific areas. These oligomannose glycans are recognized by broadly neutralizing antibodies (bNAbs) that are not thwarted by the glycan shield but, paradoxically, target it. Our site-specific glycosylation analysis of a soluble, recombinant trimer (BG505 SOSIP.664) maps the extremes of simplicity and diversity of glycan processing at individual sites and reveals a mosaic of dense clusters of oligomannose glycans on the outer domain. Although individual sites usually minimally affect the global integrity of the glycan shield, we identify examples of how deleting some glycans can subtly influence neutralization by bNAbs that bind at distant sites. The network of bNAb-targeted glycans should be preserved on vaccine antigens.


Related Papers

No related papers found

Powered by citation graph analysis